CureVac N.V.
CVACNASDAQHealthcare
$4.66
+$0.00(+0.00%)
Market Cap$1.0B
P/E Ratio—
52W High$5.72
52W Low$2.475
CureVac N.V. (CVAC) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CVAC · earnings · updated Jun 8, 2026
Latest Earnings
Q4 FY2025Report Date: Nov 24, 2025EPS Actual
-$0.10
Est. -$0.17 · +41.2%
Revenue
$0.57B
Fiscal Period
Q4 FY2025
FY ends December
Report Date
Nov 24, 2025
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
CVAC reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.07
Rev. $15.39B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.07
Rev. Est.$15.39B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▲ Q4 FY2025 | Nov 24, 2025 | -$0.17 | -$0.10 | +41.2% | $0.57B | — | — |
| ▼ Q3 FY2025 | Aug 15, 2025 | -$0.18 | -$0.30 | -66.7% | $0.00B | $0.00B | -62.7% |
| ▼ Q2 FY2025 | May 20, 2025 | -$0.16 | -$0.24 | -50.0% | $0.00B | $0.00B | -79.7% |
| ▲ Q2 FY2025 | Apr 10, 2025 | -$0.22 | -$0.15 | +31.8% | $0.01B | $0.01B | +122.7% |
| ▲ Q4 FY2024 | Nov 12, 2024 | $0.67 | $1.65 | +146.3% | $0.54B | $0.00B | +14415.3% |
| ▼ Q3 FY2024 | Aug 15, 2024 | -$0.28 | -$0.34 | -21.4% | $0.02B | $0.01B | +80.4% |
| ▼ Q2 FY2024 | May 23, 2024 | -$0.22 | -$0.34 | -54.5% | $0.01B | $0.01B | +16.5% |
| ▼ Q2 FY2024 | Apr 24, 2024 | -$0.22 | -$0.42 | -91.3% | $0.02B | $0.04B | -43.5% |
Q4 FY2025
Nov 24, 2025Beat
EPS Actual
-$0.10
EPS Est.
-$0.17
EPS Surpr.
+41.2%
Revenue
$0.57B
Q3 FY2025
Aug 15, 2025Miss
EPS Actual
-$0.30
EPS Est.
-$0.18
EPS Surpr.
-66.7%
Revenue
$0.00B
Q2 FY2025
May 20, 2025Miss
EPS Actual
-$0.24
EPS Est.
-$0.16
EPS Surpr.
-50.0%
Revenue
$0.00B
Q2 FY2025
Apr 10, 2025Beat
EPS Actual
-$0.15
EPS Est.
-$0.22
EPS Surpr.
+31.8%
Revenue
$0.01B
Q4 FY2024
Nov 12, 2024Beat
EPS Actual
$1.65
EPS Est.
$0.67
EPS Surpr.
+146.3%
Revenue
$0.54B
Q3 FY2024
Aug 15, 2024Miss
EPS Actual
-$0.34
EPS Est.
-$0.28
EPS Surpr.
-21.4%
Revenue
$0.02B
Q2 FY2024
May 23, 2024Miss
EPS Actual
-$0.34
EPS Est.
-$0.22
EPS Surpr.
-54.5%
Revenue
$0.01B
Q2 FY2024
Apr 24, 2024Miss
EPS Actual
-$0.42
EPS Est.
-$0.22
EPS Surpr.
-91.3%
Revenue
$0.02B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2026 | $-0.09 | $-0.09 | $-0.09 | 1 |
| Q4 FY2025 | $-0.07 | $-0.07 | $-0.07 | 1 |
| Q3 FY2025 | $-0.19 | $-0.18 | $-0.17 | 2 |
| Q2 FY2025 | $-0.23 | $-0.18 | $-0.14 | 2 |
| Q1 FY2025 | $-0.81 | $-0.21 | $0.39 | 2 |
| Q4 FY2024 | $-0.65 | $1.41 | $3.44 | 3 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 2 |
| Q2 FY2025 | $0.0B | $0.0B | $0.0B | 4 |
| Q1 FY2025 | $0.0B | $0.0B | $0.0B | 3 |
| Q4 FY2024 | $0.0B | $0.0B | $0.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q4 FY2025 | Nov 24, 2025 | +41.2% | $5.03 | $5.11 | +1.59% |
| ▼ Q3 FY2025 | Aug 15, 2025 | -66.7% | $5.51 | $5.48 | -0.54% |
| ▼ Q2 FY2025 | May 20, 2025 | -50.0% | $3.87 | $4.28 | +10.59% |
| ▲ Q2 FY2025 | Apr 10, 2025 | +31.8% | $2.98 | $2.86 | -4.03% |
| ▲ Q4 FY2024 | Nov 12, 2024 | +146.3% | $2.79 | $2.88 | +3.23% |
| ▼ Q3 FY2024 | Aug 15, 2024 | -21.4% | $3.31 | $3.25 | -1.81% |
| ▼ Q2 FY2024 | May 23, 2024 | -54.5% | $3.91 | $3.97 | +1.53% |
| ▼ Q2 FY2024 | Apr 24, 2024 | -91.3% | $2.60 | $2.51 | -3.46% |
Q4 FY2025+1.59%
Report Date
Nov 24, 2025
EPS Beat/Miss
+41.2%
Price Before
$5.03
Price After
$5.11
Q3 FY2025-0.54%
Report Date
Aug 15, 2025
EPS Beat/Miss
-66.7%
Price Before
$5.51
Price After
$5.48
Q2 FY2025+10.59%
Report Date
May 20, 2025
EPS Beat/Miss
-50.0%
Price Before
$3.87
Price After
$4.28
Q2 FY2025-4.03%
Report Date
Apr 10, 2025
EPS Beat/Miss
+31.8%
Price Before
$2.98
Price After
$2.86
Q4 FY2024+3.23%
Report Date
Nov 12, 2024
EPS Beat/Miss
+146.3%
Price Before
$2.79
Price After
$2.88
Q3 FY2024-1.81%
Report Date
Aug 15, 2024
EPS Beat/Miss
-21.4%
Price Before
$3.31
Price After
$3.25
Q2 FY2024+1.53%
Report Date
May 23, 2024
EPS Beat/Miss
-54.5%
Price Before
$3.91
Price After
$3.97
Q2 FY2024-3.46%
Report Date
Apr 24, 2024
EPS Beat/Miss
-91.3%
Price Before
$2.60
Price After
$2.51
Avg Beat Reaction+0.26%
Avg Miss Reaction+1.26%
Beat Rate3 / 8 quarters
Largest Move+10.59% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CVAC ends December
CureVac N.V. (CVAC) most recently reported earnings on November 24, 2025 for Q4 FY2025, posting EPS of $-0.10 — beating the analyst consensus of $-0.17 by +41.2%. The next CVAC earnings date is expected around September 1, 2026.
Each quarter, investors track CVAC earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CVAC revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CVAC's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CVAC earnings · 5 questionsCureVac N.V.'s next earnings report is expected around September 1, 2026. CVAC typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CVAC historically reports after market close (AMC).
CVAC earnings datewhen is CVAC earningsCVAC next earnings datewhen does CVAC report earningsCVAC earnings calendar
▸ Source: FMP · CureVac N.V. SEC filings · US GAAP · CureVac N.V. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026